# Célèste Lebbé

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/celeste-lebbe/

## Facts

| Field | Value |
| --- | --- |
| Citations | 91,247 |
| Field | Melanoma and MAPK Pathways |
| h-index | 96 |
| i10-index | 458 |
| Last Known Institution | Centre National de la Recherche Scientifique |
| OpenAlex ID | https://openalex.org/A5025478490 |
| ORCID iD | https://orcid.org/0000-0002-5854-7290 |
| Works | 1,248 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline](https://scholariq.org/papers/diagnosis-and-treatment-of-invasive-squamous-cell-carcinoma-of-the-skin-european/)
- [Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline](https://scholariq.org/papers/diagnosis-and-treatment-of-merkel-cell-carcinoma-european-consensus-based/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment](https://scholariq.org/papers/european-interdisciplinary-guideline-on-invasive-squamous-cell-carcinoma-of-the/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Centre National de la Recherche Scientifique](https://scholariq.org/institutions/centre-national-de-la-recherche-scientifique/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.